Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.

OBJECTIVE Adiponectin and resistin, two recently discovered adipocyte-secreted hormones, may link obesity with insulin resistance and/or metabolic and cardiovascular risk factors. We performed a cross-sectional study to investigate the association of adiponectin and resistin with inflammatory markers, hyperlipidemia, and vascular reactivity and an interventional study to investigate whether atorvastatin mediates its beneficial effects by altering adiponectin or resistin levels. RESEARCH DESIGN AND METHODS Associations among vascular reactivity, inflammatory markers, resistin, and adiponectin were assessed cross-sectionally using fasting blood samples obtained from 77 subjects who had diabetes or were at high risk to develop diabetes. The effect of atorvastatin on adiponectin and resistin levels was investigated in a 12-week-long randomized, double-blind, placebo-controlled study. RESULTS In the cross-sectional study, we confirm prior positive correlations of adiponectin with HDL and negative correlations with BMI, triglycerides, C-reactive protein (CRP), and plasma activator inhibitor (PAI)-1 and report a negative correlation with tissue plasminogen activator. The positive association with HDL and the negative association with PAI-1 remained significant after adjusting for sex and BMI. We also confirm prior findings of a negative correlation of resistin with HDL and report for the first time a positive correlation with CRP. All of these associations remained significant after adjusting for sex and BMI. No associations of adiponectin or resistin with any aspects of vascular reactivity were detected. In the interventional study, atorvastatin decreased lipid and CRP levels, but adiponectin and resistin were not specifically altered. CONCLUSIONS We conclude that adiponectin is significantly associated with inflammatory markers, in part, through an underlying association with obesity, whereas resistin's associations with inflammatory markers appear to be independent of BMI. Lipid profile and inflammatory marker changes produced by atorvastatin cannot be attributed to changes of either adiponectin or resistin.

[1]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Frühbeck,et al.  Do resistin and resistin-like molecules also link obesity to inflammatory diseases?. , 2001, Annals of internal medicine.

[3]  W. Koenig,et al.  C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[4]  L. Khaodhiar,et al.  Chronic systemic inflammation in overweight and obese adults. , 2000, JAMA.

[5]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[6]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[7]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[8]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[9]  NoriyukiOuchi,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001 .

[10]  大内 乗有.  Novel modulator for endothelial adhesion molecules : Adipocyte-derived plasma protein adiponectin , 2001 .

[11]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[12]  D. Illingworth,et al.  Drug treatment of dyslipoproteinemia. , 1994, The Medical clinics of North America.

[13]  J. Kastelein,et al.  Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. , 2000, The American journal of cardiology.

[14]  David M. Herrington,et al.  Erratum: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force (Journal of American College of Cardiology (2002) 39 (257-265)) , 2002 .

[15]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[16]  C. Stehouwer,et al.  Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. , 2002, Atherosclerosis.

[17]  A. Xu,et al.  Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  S. Maruoka,et al.  Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. , 2002, European journal of endocrinology.

[19]  S. Devaraj,et al.  α-tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients , 2002 .

[20]  T. Willson,et al.  Adipose Tissue Resistin Expression Is Severely Suppressed in Obesity and Stimulated by Peroxisome Proliferator-activated Receptor γ Agonists* , 2001, The Journal of Biological Chemistry.

[21]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[22]  J. Navarro-Antolín,et al.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.

[23]  NoriyukiOuchi,et al.  Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003 .

[24]  J. Chan,et al.  Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  Philippe Froguel,et al.  Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation* , 2002, The Journal of Biological Chemistry.

[26]  V. Hána,et al.  Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance , 2003, Clinical endocrinology.

[27]  B. Howard,et al.  Diabetes and cardiovascular disease , 2000, Annual review of medicine.

[28]  C. Kahn,et al.  Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. , 2002, Developmental cell.

[29]  R. Saouaf,et al.  Aerobic Exercise Capacity Remains Normal Despite Impaired Endothelial Function in the Micro- and Macrocirculation of Physically Active IDDM Patients , 1997, Diabetes.

[30]  J. Isaacsohn,et al.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. , 1996, JAMA.

[31]  C. Bogardus,et al.  Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. , 2002, Diabetes.

[32]  F. Peale,et al.  FIZZ1, a novel cysteine‐rich secreted protein associated with pulmonary inflammation, defines a new gene family , 2000, The EMBO journal.

[33]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[34]  R. A. Norman,et al.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.

[35]  J. Chan,et al.  The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. , 2003, The Journal of clinical investigation.

[36]  H. Lodish,et al.  ACRP30, a new hormone controlling fat and glucose metabolism. , 2002, European journal of pharmacology.

[37]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[38]  M. Alessi,et al.  Fibrinolysis and atherothrombosis , 1993 .

[39]  L. Khaodhiar,et al.  The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[40]  J. Fernández-Real,et al.  Adiponectin is associated with vascular function independent of insulin sensitivity. , 2004, Diabetes care.

[41]  M. Lazar,et al.  Resistin and obesity-associated insulin resistance , 2002, Trends in Endocrinology & Metabolism.

[42]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[43]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[44]  T. Matsumura,et al.  HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. , 1997, Atherosclerosis.

[45]  Y. Nakano,et al.  Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. , 1996, Journal of biochemistry.

[46]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[47]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[48]  T. Funahashi,et al.  Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. , 2003, Diabetes care.

[49]  T. Saruta,et al.  Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. , 2002, Clinical science.